Ida Kappel Buhl
YOU?
Author Swipe
View article: HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, Rigshospitalet
HRD status variation in consecutive tumour biopsies in a pan-cancer cohort: a descriptive single-center study including patients from the Phase 1 Unit, Copenhagen University Hospital, Rigshospitalet Open
When testing for HRD, sensitivity to normal tissue in tumour samples has proven more consequential than previously expected. Based on our findings, HRD status rarely changes over time, and changes in HRD scores may not reflect a genuine bi…
View article: 87P Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting
87P Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting Open
HG-NEN is a heterogeneous group of rare cancers, including neuroendocrine carcinoma (NEC) and high-grade neuroendocrine tumors (NET G3). HG-NENs are characterized by poor differentiation, rapid growth, limited treatment options and poor pr…
View article: 17P Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients
17P Homologous recombination deficiency status in consecutive tumor biopsies in late-stage cancer patients Open
Homologous recombination deficiency (HRD) can predict sensitivity to platinum-based chemotherapy and PARP-inhibitors in cancer patients. HRD testing is currently used clinically to decide the optimal course of treatment of high-grade ovari…
View article: Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative Group
Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative Group Open
Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here mul…
View article: A Drug Response Predictor to Guide Treatment for Breast Cancer
A Drug Response Predictor to Guide Treatment for Breast Cancer Open
View article: Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts
Molecular prediction of adjuvant cisplatin efficacy in Non-Small Cell Lung Cancer (NSCLC)—validation in two independent cohorts Open
Profiles derived from snap-frozen and FFPE NSCLC tissue were prognostic and predictive in the patients that received cisplatin and vinorelbine but not in the cohort that did not receive adjuvant treatment.
View article: Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer
Multigene expression profile for predicting efficacy of cisplatin and vinorelbine in non-small cell lung cancer Open
View article: Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data
Cell Line Derived 5-FU and Irinotecan Drug-Sensitivity Profiles Evaluated in Adjuvant Colon Cancer Trial Data Open
The irinotecan predictor had no predictive value. The 5-FU predictor was prognostic in stage III patients in PETACC-3 but not in stage II patients with no adjuvant therapy. This suggests a potential predictive ability of the 5-FU sensitivi…